Although far less frequent, MET mutations have also been described as a mechanism for c-MET pathway activation in gastric cancer and in other malignancies.[14, 15] The recognition of this subset of GE cancer with its poor prognosis is important for referring affected patients to clinical trials with experimental therapies. This evidence concerns the gene MET and gastric cancer.